SV

Street Verdict

Analyst Scorecard

COHANCE · NSE

Cohance Lifesciences Limited

₹462.3

+0.62% (+₹2.85)

Prev. close

₹459.45

Volume

3,18,955

Delivery %

46.2%

As of

20 Nov 2026

Price history

₹462.3+₹7.1 (+1.56%) · 3M
18 Aug 2026 → 20 Nov 2026
43044045046047048018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Cohance Lifesciences Limited

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Umang Vohra B.E., M.B.A.

Headquarters

Hyderabad

Key stats

Market cap

₹17,234.10 Cr

P/E ratio (TTM)

165.0

Dividend yield

0.00%

EPS (TTM)

₹2.73

Beta (1Y · daily vs NIFTY 50)

0.84

Beta (5Y · monthly vs NIFTY 50)

1.15

Shares float

13.81 Cr

EPS · quarter ended Jun 2026

₹-0.65

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%10%20%30%40%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

05101520₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0246₹0%100%200%300%17 Feb 2113 Aug 2115 Feb 2213 May 2209 Sept 22
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-200%0%200%400%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

Left off as not meaningful (growth from a very small base, beyond ±400%): Trade receivables FY25 (+478%).

05 · Capital Structure & Asset Utilization

0 Cr2000 Cr4000 Cr6000 Cr₹0×0.2×0.4×0.6×0.8×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2000 Cr4000 Cr6000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr200 Cr400 Cr600 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,009.72 Cr₹1,320.22 Cr₹1,340.33 Cr₹1,034.06 Cr₹2,526.22 Cr₹2,268.55 Cr
EBITDA
₹454.72 Cr₹671.81 Cr₹620.53 Cr₹467.22 Cr₹847.42 Cr₹431.61 Cr
₹362.00 Cr₹453.80 Cr₹411.29 Cr₹300.28 Cr₹487.34 Cr₹179.23 Cr
Diluted EPS
₹14.23₹17.83₹16.16₹11.8₹12.68₹4.68

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,474.00 Cr₹1,830.00 Cr₹1,966.00 Cr₹2,254.00 Cr₹5,480.00 Cr₹5,727.00 Cr
₹143.04 Cr₹97.13 Cr₹70.34 Cr₹65.01 Cr₹485.93 Cr₹400.49 Cr
Stockholders' equity
₹1,180.00 Cr₹1,527.00 Cr₹1,735.00 Cr₹2,050.00 Cr₹3,648.00 Cr₹3,911.00 Cr

CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹383.00 Cr₹330.00 Cr₹457.00 Cr₹358.00 Cr₹673.00 Cr₹368.00 Cr
Investing cash flow
₹-311.40 Cr₹-136.14 Cr₹-194.84 Cr₹-362.35 Cr₹-389.70 Cr₹-254.57 Cr
₹-76.00 Cr₹-156.00 Cr₹-242.00 Cr₹-14.00 Cr₹-327.00 Cr₹-165.00 Cr
Capital expenditure
₹-111.00 Cr₹-75.00 Cr₹-286.00 Cr₹-52.00 Cr₹-317.00 Cr₹-220.00 Cr
End cash position
₹7.18 Cr₹44.56 Cr₹64.80 Cr₹47.23 Cr₹96.65 Cr₹49.14 Cr

Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 23(10Q)Mar 24–Mar 25(5Q)May 25–Jun 25(2Q)Sep 25–Jun 26(4Q)
Promoter60.00%50.10%66.41%57.49%
Public40.00%49.90%33.59%42.51%
Employee trusts0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Cohance Lifesciences Limited₹17,086.80 Cr₹440.35163.64.374.6%0.10-12.8%-40.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

COHANCE

Cohance Lifesciences Ltd (BOM:543064) (Q2 2027) Earnings Call Hi

GuruFocus · 10 days ago

COHANCE

Cohance Lifesciences: Jasub holding rises to 5.18% stake

Multibagg AI · 11 days ago